P. Miller

发表

Bone mineral density thresholds for pharmacological intervention to prevent fractures.

E. Barrett-Connor, E. Siris, Ya-ting Chen, 2004, Archives of internal medicine.

Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women

H. Genant, P. Miller, P. Ross, 1993, Osteoporosis International.

Safety of parathyroid hormone for the treatment of osteoporosis

P. Miller, 2008, Current osteoporosis reports.

Osteoporosis and Fracture Risk in Women of Different Ethnic Groups

E. Barrett-Connor, E. Siris, T. Abbott, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.

E. Barrett-Connor, E. Siris, T. Abbott, 2001, JAMA.

Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure

S. Boonen, I. Reid, P. Delmas, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures

Paul D. Miller, E. Barrett-Connor, E. Siris, 2004 .

Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1‐Year Results From the MOBILE Study

Dieter Felsenberg, C. Cooper, J. Reginster, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Standards for performing DXA in individuals with secondary causes of osteoporosis.

Jacques P. Brown, N. Watts, J. Bilezikian, 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy.

S. Silverman, M. Hochberg, P. Miller, 2010, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

H K Genant, Jacques P. Brown, H. Genant, 1999, JAMA.

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

P Geusens, H Zippel, P. Geusens, 2001, The New England journal of medicine.

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis

E. Glass, P. Miller, M. Heathman, 2010, Calcified Tissue International.

Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007.

C. Cooper, M. Hochberg, J. Bilezikian, 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Taxonomy of rare genetic metabolic bone disorders

J. Kaufman, N. Watts, J. Bilezikian, 2015, Osteoporosis International.

Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women

P. Miller, G. Constantine, R. Kagan, 2016, Menopause.

Chronic kidney disease and the skeleton

P. Miller, 2014, Bone Research.

Encrustation of intraprostatic stents--a comparative study.

P. Miller, R. Kirby, P. Crocker, 1992, British Journal of Urology.

Bone Densitometry in the Elderly

P. Miller, T. Masud, 2000 .

Proceedings of the 2011 Santa Fe Bone symposium.

E. McCloskey, J. Bilezikian, E. Orwoll, 2012, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Bisphosphonates pharmacology and use in the treatment of osteoporosis

N. Watts, P. Miller, Dima L. Diab, 2021, Marcus and Feldman's Osteoporosis.

Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates

N. Pannacciulli, P. Miller, A. Chines, 2019, Osteoporosis International.

Remodeling‐ and Modeling‐Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study

Jacques P. Brown, R. Recker, R. Lindsay, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.

Jacques P. Brown, R. Recker, R. Lindsay, 2016, The Journal of clinical endocrinology and metabolism.

Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.

Jacques P. Brown, R. Recker, R. Lindsay, 2012, The Journal of clinical endocrinology and metabolism.

Improved precision with Hologic Apex software

H. Genant, Y. Lu, J. Shepherd, 2008, Osteoporosis International.

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.

M. Hochberg, P. Miller, P. Ross, 2002, The Journal of clinical endocrinology and metabolism.

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.

J. S. San Martin, P. Miller, M. Peacock, 2011, The Journal of clinical endocrinology and metabolism.

Bone Density and Fracture Risk in Primary Hyperparathyroidism

P. Miller, E. Lewiecki, 2012 .

Determinants of Bone Strength

P. Miller, G. Kiebzak, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.

P. Miller, M. McClung, E. Lewiecki, 2017, The American journal of medicine.

Bone disease in CKD: a focus on osteoporosis diagnosis and management.

P. Miller, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Chronic kidney disease and osteoporosis: evaluation and management.

P. Miller, 2014, BoneKEy reports.

Fracture risk assessment in patients with chronic kidney disease

S. Jamal, P. Miller, S. West, 2012, Osteoporosis International.

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study

R. Recker, J. Stakkestad, P. Miller, 2012, Osteoporosis International.

Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.

P. Ward, P. Miller, J. Body, 2008, Clinical and experimental rheumatology.

Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment

E. Schwartz, P. Miller, J. Krege, 2006, Osteoporosis International.

Perspective: Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw

P. Miller, S. Baim, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Meeting report from the IOF world congress on osteoporosis

C. Cooper, J. Eisman, G. Rodan, 2002 .

Diagnostic agreement at the total hip using different DXA systems and the NHANES III database.

P. Miller, N. Binkley, E. Lewiecki, 2007, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Recalculation of the NHANES Database SD Improves T‐Score Agreement and Reduces Osteoporosis Prevalence

M. Drezner, R. Gangnon, J. Shepherd, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel.

B. Riggs, N. Watts, R. Lindsay, 1999, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases.

J. Shepherd, J. Bilezikian, P. Miller, 2017, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Long-term extension trials to prove the efficacy and safety of bisphosphonates

P. Miller, 2014 .

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

D. Bauer, P. Miller, M. McClung, 2013, The American journal of medicine.

2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases.

N. Watts, W. Leslie, P. Miller, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Benefits and risks of bisphosphonate therapy for osteoporosis.

R. Recker, S. Khosla, D. Dempster, 2012, The Journal of clinical endocrinology and metabolism.

Diseases of Mineral Metabolism and Bone: Emerging Therapeutics for Postmenopausal Osteoporosiss

P. Miller, 2012 .

Bone strength and surrogate markers: The first, second, and third fiddle

P. Miller, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

All bisphosphonates are (or may not be) the same: potential reasons for clinical differences.

P. Miller, 2010, Journal of women's health.

Clinical Value of Monitoring BMD in Patients Treated With Bisphosphonates for Osteoporosis

P. Geusens, N. Watts, R. Recker, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The role of bone biopsy in patients with chronic renal failure.

P. Miller, 2008, Clinical journal of the American Society of Nephrology : CJASN.

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

J. Reginster, P. Miller, S. Epstein, 2008, Current medical research and opinion.

Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data

P. Miller, 2008, Current medical research and opinion.

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.

P. Miller, P. Kothawala, M. Bernal, 2007, Clinical therapeutics.

Monitoring osteoporosis therapies

P. Miller, 2007, Current osteoporosis reports.

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker

P. Miller, W. A. Blumentals, M. Pazianas, 2008, Osteoporosis International.

Renal safety of intravenous bisphosphonates in the treatment of osteoporosis

P. Miller, E. Lewiecki, 2007, Expert opinion on drug safety.

Chapter 20 – Combination Therapy for Osteoporosis: What Do the Data Show Us?

P. Miller, 2006 .

The use of teriparatide and PTH(1–84) for the treatment of osteoporosis

P. Miller, R. Wagman, 2006, Clinical Reviews in Bone and Mineral Metabolism.

Treatment of metabolic bone disease in patients with chronic renal disease: A perspective for rheumatologists

P. Miller, 2005, Current rheumatology reports.

Treatment of osteoporosis in chronic kidney disease and end-stage renal disease

P. Miller, 2005, Current osteoporosis reports.

Clinical use of teriparatide in the real world: initial insights.

J. Bilezikian, P. Miller, S. T. Harris, 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Combination therapy for osteoporosis: parathyroid hormone and bisphosphonates

P. Miller, 2004 .

Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis

P. Miller, 2003, Expert opinion on pharmacotherapy.

Alendronate Improves Bone Mineral Density in Elderly Women with Osteoporosis Residing in Long-Term Care Facilities

T. Schnitzer, D. Schneider, P. Miller, 2002, Annals of Internal Medicine.

Tolerability of risedronate in postmenopausal women intolerant of alendronate

S. Silverman, J. Adachi, P. Miller, 2001, Aging.

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

P. Miller, R. Wasnich, 2000, The Journal of clinical endocrinology and metabolism.

Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms.

P. Miller, M. Ettinger, A. Licata, 2000, Clinical therapeutics.

Management of osteoporosis.

P. Miller, 1999, Disease-a-month : DM.

Clinical Application of Bone Densitometry

P. Miller, S. T. Harris, 1998 .

The 2002 Canadian bone densitometry recommendations: take-home messages.

Jacques P. Brown, N. Watts, W. Leslie, 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Vitamin D, calcium, and cardiovascular mortality: a perspective from a plenary lecture given at the annual meeting of the American Association of Clinical Endocrinologists.

P. Miller, 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBDs): What the Endocrinologist Needs to Know.

N. Watts, P. Miller, B. Clarke, 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

CHRONIC KIDNEY DISEASE MINERAL AND BONE DISORDERS (CKD-MBD) WHAT THE ENDOCRINOLOGIST NEEDS TO KNOW Running title: CKD-MBD and Endocrinologists

N. Watts, P. Miller, B. Clarke, 2013 .

New or worsening lumbar spine vertebral fractures increase lumbar spine bone mineral density and falsely suggest improved skeletal status.

L. Lenchik, P. Miller, J. Krege, 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population

P. Miller, C. Rosen, S. Bonnick, 1996, Calcified Tissue International.

Proceedings of the 2021 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis and Metabolic Bone Diseases.

P. Anderson, J. Bilezikian, P. Miller, 2021, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics.

P. Miller, M. Pazianas, 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The CKD‐MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management

P. Miller, M. Pazianas, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management

P. Miller, M. Pazianas, 2020, Journal of bone metabolism.

Clinical Skeletal Syndromes Associated with Parathyroid Disorders in Chronic Kidney Disease

S. Jamal, P. Miller, S. Sprague, 2015 .

Bone and Kidney Disease: Diagnostic and Therapeutic Implications

S. Jamal, P. Miller, S. West, 2012, Current Rheumatology Reports.

Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease

P. Miller, P. Ebeling, E. Franek, 2020, The Journal of clinical endocrinology and metabolism.

Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study

E. Barrett-Connor, E. Siris, Ya-ting Chen, 2003, Menopause.

Rapid Loss of Hip Fracture Protection After Estrogen Cessation: Evidence From the National Osteoporosis Risk Assessment

E. Barrett-Connor, E. Siris, Ya-ting Chen, 2004, Obstetrics and gynecology.

Bone Mass Measurement Techniques in Clinical Practice

P. Miller, B. Sterkel, 2000 .

Comparison of BMD precision for Prodigy and Delphi spine and femur scans

H. Genant, Y. Lu, J. Shepherd, 2006, Osteoporosis International.

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

C. Christiansen, A. Harris, E. Lau, 2019, Bone.

Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis.

P. Miller, M. McClung, E. Lewiecki, 2019, The American journal of medicine.

Editorial: greater risk, greater benefit--true or false?

P. Miller, 2003, Journal of Clinical Endocrinology and Metabolism.

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

H. Genant, N. Watts, R. Jackson, 1993, The American journal of medicine.

A comparative trial of risedronate vs. etidronate in the treatment of patients with Paget’s disease of bone

Jacques P. Brown, E. Siris, P. Miller, 1999 .

Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis.

D. Bauer, P. Miller, M. McClung, 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

W. Mysiw, H. Genant, N. Watts, 1990, The New England journal of medicine.

Osteoporosis: An Overview

P. Miller, M. McClung, S. Papapoulos, 2018 .

Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies

J. Reginster, S. Silverman, D. Felsenberg, 2013, Osteoporosis International.

Bone Mass Measurements The Case for Selected Screening?

P. Miller, S. Epstein, 1997, Trends in Endocrinology & Metabolism.

Guidelines for the clinical utilization of bone mass measurement in the adult population

P. Miller, C. Rosen, S. Bonnick, 1995, Calcified Tissue International.

Bone Mass Measurement

P. Miller, 2004 .

Standards and guidelines for performing central dual X-ray densitometry from the Canadian Panel of International Society for Clinical Densitometry.

N. Watts, W. Leslie, P. Miller, 2002, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Prediction of fracture risk. I: Bone density.

P. Miller, M. McClung, 1996, The American journal of the medical sciences.

Clinical Interpretation and Utility of Bone Densitometry

P. Miller, 1996 .

Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk.

P. Miller, E. Lewiecki, E. Lewiecki, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis

B. Mitlak, D. Dempster, Hua Zhou, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial

Jacques P. Brown, R. Recker, R. Lindsay, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Management of Osteoporosis in Patients with Chronic Kidney Disease

P. Miller, 2018, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.

Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.

P. Miller, E. McCarthy, 2015, Seminars in arthritis and rheumatism.

Osteoporosis update from the 2010 santa fe bone symposium.

R. Marcus, N. Watts, S. Khosla, 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

An approach for identifying postmenopausal women age 50–64 years at increased short-term risk for osteoporotic fracture

T. Weiss, E. Barrett-Connor, E. Siris, 2007, Osteoporosis International.

A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis

P. Miller, E. Lewiecki, S. Goemaere, 2018, The Journal of clinical endocrinology and metabolism.

Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA)

L. Markson, E. Barrett-Connor, E. Siris, 2008, Osteoporosis International.

Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis

P. Miller, M. McClung, N. Harvey, 2018, Menopause.

Estimation of Long‐Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX‐ and Virtual Twin‐Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials

J. Kanis, E. Siris, N. Pannacciulli, 2020, JBMR plus.

Observations following discontinuation of long-term denosumab therapy

P. Miller, M. McClung, E. Lewiecki, 2017, Osteoporosis International.

Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension

Jacques P. Brown, I. Reid, P. Miller, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

P. Miller, M. Peacock, M. McClung, 2012, Osteoporosis International.

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

J. S. San Martin, J. Gallagher, P. Miller, 2011, The Journal of clinical endocrinology and metabolism.

Update on Rationale and Development of New Agents for the Treatment of Osteoporosis

R. Recker, J. Bilezikian, P. Miller, 2010 .

2009 Santa Fe Bone symposium.

R. Recker, J. Bilezikian, P. Miller, 2010, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Risedronate reduces hip fractures in patients with low femoral neck bone mineral density

J. Reginster, R. Eastell, P. Miller, 1999 .

Expanding the list of etiologic factors for osteoporosis in men.

P. Miller, 1997, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

A. Díez-Pérez, J. Kanis, D. Bauer, 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis?

L. Lenchik, C. Njeh, P. Miller, 2002, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

R. Recker, P. Miller, M. McClung, 2009, Bone.

Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction

P. Miller, 2005, Current osteoporosis reports.

Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide.

R. Marcus, J. Bilezikian, P. Miller, 2007, The Journal of clinical endocrinology and metabolism.

Clinical Performance of a Highly Portable, Scanning Calcaneal Ultrasonometer

S. Cheng, E. Orwoll, P. Miller, 2001, Osteoporosis International.

Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate

P. Delmas, R. Recker, P. Miller, 2010, Calcified Tissue International.

A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone

Jacques P. Brown, E. Siris, P. Miller, 1999 .

Osteoporosis Associated with Systemic Illness and Medications

P. Miller, 2003 .

Bisphosphonates for the Prevention and Treatment of Corticosteroid-Induced Osteoporosis

P. Miller, 2001, Osteoporosis International.

Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates

N. Watts, P. Miller, E. McCarthy, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The role of osteoanabolic agents in the management of patients with osteoporosis

P. Miller, M. McClung, E. Lewiecki, 2022, Postgraduate medicine.

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism

D. Bauer, T. Clemens, J. Bilezikian, 2009 .

Treatment of alcoholic acidosis: the role of dextrose and phosphorus.

P. Miller, R. Heinig, C. Waterhouse, 1978, Archives of internal medicine.

Comparative effect of diuretics on renal water excretion in hyponatraemic oedematous disorders.

R. Schrier, P. Miller, J. Gordon, 1982, Clinical science.

Hormonal control of renal water excretion.

T. Berl, R. Anderson, R. Schrier, 1976, Kidney international.

Role of the renin-angiotensin system in post-transplantation hypertension in patients with multiple kidneys.

R. Schrier, P. Miller, S. Linas, 1978, The New England journal of medicine.

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.

M. Hochberg, P. Miller, P. Ross, 2002, The Journal of clinical endocrinology and metabolism.

Acute metabolic alkalosis perpetuating hypercarbia. A role for acetazolamide in chronic obstructive pulmonary disease.

P. Miller, A. S. Berns, 1977, JAMA.

Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.

D. Felsenberg, P. Miller, S. T. Harris, 2005, The Journal of rheumatology.

Transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia: results obtained with the Urologix T3 device

P. Miller, K. Parsons, E. Ramsey, 1998, World journal of urology.

A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years

Jacques P. Brown, I. Reid, P. Miller, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

Jacques P. Brown, I. Reid, P. Miller, 2005, The New England journal of medicine.

Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum.

P. Delmas, P. Miller, F. Singer, 1994, Clinical chemistry.

Bone densitometry in asymptomatic primary hyperparathyroidism.

J. Bilezikian, P. Miller, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.

P. Miller, 2004, The New England journal of medicine.

A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis

P. Miller, 2011, Therapeutic advances in musculoskeletal disease.

Denosumab: Anti-RANKL antibody

P. Miller, 2009, Current osteoporosis reports.

Central, renal and adrenal effects of lithium in man.

S. Dubovsky, R. Schrier, P. Miller, 1979, American Journal of Medicine.

Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients.

R. Schrier, P. Miller, S. Linas, 1980, JAMA.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY.

N. Watts, M. Kleerekoper, Rachel Pessah-Pollack, 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Proceedings of the 2022 Santa Fe Bone Symposium: Current Concepts in the Care of Patients with Osteoporosis and Metabolic Bone Diseases.

M. Bouxsein, J. Bilezikian, P. Miller, 2022, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Continuation of Bisphosphonate Therapy for Osteoporosis beyond 5 Years.

R. Eastell, P. Miller, L. L. Chang, 2022, New England Journal of Medicine.

Bone AnABolic TherApy for osTeoporosis

P. Miller, C. Langman, B. Messinger-Rapport, 2022 .

Simple Test for Hypercalciuria

G. Meadors, P. Miller, D. Sherrard, 1975 .

Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.

D. Felsenberg, P. Miller, E. Lewiecki, 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease

I. Reid, J. Adachi, P. Miller, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report.

S. Jamal, P. Miller, D. Goltzman, 2015, American Journal of Kidney Diseases.

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker: reply to Yarom and Elad

P. Miller, W. A. Blumentals, M. Pazianas, 2008, Osteoporosis International.

Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing

R. Kumar, F. Rauch, P. Miller, 2021, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Burosumab for the Treatment of Tumor‐Induced Osteomalacia

R. Kumar, F. Rauch, P. Miller, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

ZOLEDRONOVAYa KISLOTA V PROFILAKTIKE POTERI KOSTNOY TKANI U zhENShchIN POSTMENOPAUZAL'NOGO VOZRASTA S OSTEOPENIEY

C. Benhamou, P. Miller, P. Mesenbrink, 2011 .

The history of bone densitometry.

P. Miller, 2017, Bone.

Design of NORA, the National Osteoporosis Risk Assessment Program: a longitudinal US registry of postmenopausal women.

E. Barrett-Connor, E. Siris, T. Abbott, 1998, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

Hypomagnesemia. Suppression of secondary hyperparathyroidism in chronic renal failure.

P. Miller, R. Krebs, B. J. Neal, 1979, Journal of the American Medical Association (JAMA).

Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.

P. Miller, M. McClung, A. Kaunitz, 2006, Contraception.

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.

P. Kulkarni, A. Papaioannou, P. Miller, 2002, The Journal of clinical endocrinology and metabolism.

National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist.

N. Watts, P. Miller, E. Lewiecki, 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Bone Density Testing Is the Best Way to Monitor Osteoporosis Treatment.

P. Miller, E. Lewiecki, M. Rothman, 2017, The American journal of medicine.

New possibilities for diagnosis and treatment of osteoporosis.

P. Miller, 2001, International journal of fertility and women's medicine.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

C. Christiansen, A. Harris, P. Alexandersen, 2016, JAMA.

How useful are measures of BMD and bone turnover?*

M. Hochberg, P. Miller, L. Wehren, 2005, Current medical research and opinion.

Hypodipsia in geriatric patients.

P. Miller, R. Krebs, B. J. Neal, 1982, The American journal of medicine.

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial

C. Christiansen, D. Black, J. Bilezikian, 2017, Mayo Clinic proceedings.

Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

P. Miller, M. McClung, E. Lewiecki, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.

S. Boonen, P. Miller, P. Mesenbrink, 2008, Kidney international.

Is There a Role for Bisphosphonates in Chronic Kidney Disease?

P. Miller, 2007, Seminars in dialysis.

Fracture incidence in a large cohort of men age 30 years and older with osteoporosis

C. O’Malley, P. Miller, U. Gruntmanis, 2015, Osteoporosis International.

A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.

J. Reginster, E. Orwoll, P. Miller, 2015, The Journal of clinical endocrinology and metabolism.

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

J. Reginster, S. Boonen, A. Grauer, 2012, The Journal of clinical endocrinology and metabolism.

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

D. Bauer, D. Dempster, E. Orwoll, 2005, Endocrine reviews.

Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children.

Jacques P. Brown, N. Watts, W. Leslie, 2004, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment.

Jacques P. Brown, S. Cummings, J. Adachi, 2004, Clinical therapeutics.

Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis.

N. Watts, S. Ott, P. Miller, 1994, The Journal of clinical endocrinology and metabolism.

Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.

P. Miller, 2005, Clinical therapeutics.

Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis.

C. Gordon, J. Bilezikian, P. Miller, 2018, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.

G. Dalsky, D. Donley, J. S. San Martin, 2005, Archives of internal medicine.

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

H. Genant, N. Watts, P. Miller, 1997, The American journal of medicine.

Meeting report from the 24th annual meeting of the American society for bone and mineral research

D. Black, D. Vanderschueren, S. Ralston, 2002 .

Management of severe osteoporosis

P. Miller, 2016, Expert opinion on pharmacotherapy.

Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long‐term continuation on bone turnover and fracture risk—a perspective

S. Boonen, I. Reid, P. Sambrook, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bisphosphonates and bone quality.

P. Miller, M. Pazianas, Stefan van der Geest, 2014, BoneKEy reports.

Rehabilitation of Patients with fRagility-Related fRactuRes

P. Miller, C. Langman, B. Messinger-Rapport, 2014 .

Polyuric prerenal failure.

P. Miller, R. Krebs, B. J. Neal, 1980, Archives of internal medicine.

Alendronate for the treatment of osteoporosis in men.

E. Orwoll, P. Miller, P. Pietschmann, 2000, The New England journal of medicine.

PINP as a biological response marker during teriparatide treatment for osteoporosis

J. M. Harris, N. Lane, P. Miller, 2014, Osteoporosis International.

Use of the ASI titanium stent in the management of bladder outflow obstruction due to benign prostatic hyperplasia.

P. Miller, I. Eardley, R. Kirby, 1992, The Journal of urology.

RANKL Inhibition With Denosumab Does Not Influence 3‐Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk

D. Kiel, C. Christiansen, P. Miller, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Pathogenic mechanisms in early norepinephrine-induced acute renal failure: functional and histological correlates of protection.

R. Schrier, P. Miller, R. Bulger, 1978, Kidney international.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016.

N. Watts, M. Kleerekoper, Rachel Pessah-Pollack, 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Secondary and tertiary hyperparathyroidism.

S. Jamal, P. Miller, Sophie A Jamal, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Hypercalcemia: Diagnosis and Treatment

P. Miller, 2002 .

RENAL CELL CARCINOMA: UNUSUAL SYSTEMIC MANIFESTATIONS

P. Gabow, W. D. Kaehny, R. Schrier, 1976, Medicine.

Rib fracture as a predictor of future fractures in young and older postmenopausal women: National Osteoporosis Risk Assessment (NORA)

C. McHorney, S. Sen, E. Barrett-Connor, 2012, Osteoporosis International.

Denosumab in Postmenopausal Women with Low Bone Mineral Density

P. Miller, M. Peacock, M. McClung, 2007 .

Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2‐Yr Results of a Randomized, Double‐Blind, Placebo‐, and Active‐Controlled Study

C. Christiansen, P. Delmas, H. C. Hoeck, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Vertebral Fractures: Clinical Importance and Management.

D. Bauer, J. Schousboe, P. Miller, 2016, The American journal of medicine.

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

Jacques P. Brown, S. Cummings, J. Reginster, 2016, The Journal of clinical endocrinology and metabolism.

Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis

Harry K. Genant, Paul D. Miller, Bess Dawson-Hughes, 1999, Osteoporosis International.

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

J. S. San Martin, P. Miller, M. McClung, 2008, Bone.

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density

B. Mitlak, J. Schense, P. Miller, 2021, Clinical Drug Investigation.

Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial

B. Mitlak, J. Bilezikian, P. Miller, 2019, Current medical research and opinion.

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

R. Rizzoli, B. Mitlak, J. Bilezikian, 2018, The Journal of clinical endocrinology and metabolism.

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

P. Miller, M. McClung, G. Hattersley, 2017, Calcified Tissue International.

The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA)

S. K. Brenneman, E. Barrett-Connor, E. Siris, 2006, Osteoporosis International.

Anti-resorptives in the management of osteoporosis.

P. Miller, 2008, Best practice & research. Clinical endocrinology & metabolism.

Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis.

P. Kostenuik, S. Khosla, L. Giangregorio, 2019, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Bone Mineral Density in Chronic Kidney Disease Use and Misuse

S. Jamal, P. Miller, S. West, 2012, Clinical Reviews in Bone and Mineral Metabolism.

Diagnosis and treatment of osteoporosis in chronic renal disease.

P. Miller, 2009, Seminars in nephrology.

Effects of denosumab on fracture and bone mineral density by level of kidney function

S. Cummings, S. Boonen, S. Jamal, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Proceedings of the 2015 Santa Fe Bone Symposium: Clinical Applications of Scientific Advances in Osteoporosis and Metabolic Bone Disease.

R. Baron, W. Leslie, J. Bilezikian, 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Bone densitometry: the best way to detect osteoporosis and to monitor therapy.

J. Bilezikian, P. Miller, C. M. Kulak, 1999, The Journal of clinical endocrinology and metabolism.

Long‐Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate

Jacques P. Brown, I. Reid, P. Miller, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.

E. Siris, P. Miller, P. Bekker, 1999, The American journal of medicine.

26 – Renal Bone Diseases

E. Lerma, P. Miller, 2005 .

Management of Fractures in Men with Impaired Renal Function

P. Miller, 2010 .

Traumatic renal artery thrombosis.

R. Schrier, P. Miller, R. Cosby, 1986, The American journal of medicine.

Fragility fractures in chronic kidney disease: An opinion-based approach

P. Miller, 2009, Cleveland Clinic Journal of Medicine.

Renal safety in patients treated with bisphosphonates for osteoporosis: A review

S. Boonen, R. Eastell, S. Jamal, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The kidney and bisphosphonates.

P. Miller, 2011, Bone.

Clinical Use of Bone Densitometry

Paul D. Miller, Sydney Lou Bonnick, P. Miller, 2013 .

CHAPTER 62 – Clinical Use of Bone Densitometry

P. Miller, K. Faulkner, 2008 .

Predictive Value of Low BMD for 1‐Year Fracture Outcomes Is Similar for Postmenopausal Women Ages 50‐64 and 65 and Older: Results From the National Osteoporosis Risk Assessment (NORA)

E. Barrett-Connor, E. Siris, Ya-ting Chen, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Osteoporosis update from the 2012 Santa Fe Bone Symposium.

M. Bouxsein, R. Marcus, J. Bilezikian, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Importance of precision in bone density measurements.

E. Siris, R. Lindsay, M. Kleerekoper, 2001, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Discordance in patient classification using T-scores.

P. Miller, K. Faulkner, E. von Stetten, 1999, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Osteoporosis update: proceedings of the 2013 Santa Fe Bone Symposium.

D. Kiel, L. Bonewald, J. Bilezikian, 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

Jacques P. Brown, I. Reid, J. S. San Martin, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

An approach to identifying osteopenic women at increased short-term risk of fracture.

E. Barrett-Connor, E. Siris, Ya-ting Chen, 2004, Archives of internal medicine.

Update on osteoporosis from the 2014 Santa Fe Bone symposium

E. Shane, J. Bilezikian, D. Hans, 2015, Endocrine research.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

S. Boonen, P. Miller, E. Eriksen, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.

J. Kanis, W. Leslie, J. Adachi, 2011, Journal of clinical densitometry.

Vertebral Fracture Risk Is Reduced in Women Who Lose Femoral Neck BMD With Teriparatide Treatment

N. Watts, P. Miller, K. Krohn, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

M. Drezner, C. Cooper, C. Christiansen, 2005, Annals of the rheumatic diseases.

Clinical Management of Vertebral Compression Fractures.

P. Miller, 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

“Evidence-based” or “logic-based” medicine?

N. Watts, J. Bilezikian, P. Miller, 2010, Osteoporosis International.

Chapter 89 – Controversial Issues in Bone Densitometry

P. Miller, 2008 .

Skeletal health and bone strength: DXA and beyond growth for the Journal of Clinical Densitometry.

P. Miller, 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Guidelines for the diagnosis of osteoporosis: T-scores vs fractures

P. Miller, 2007, Reviews in Endocrine and Metabolic Disorders.

Analysis of 1-year Vertebral Fracture Risk Reduction Data in Treatments for Osteoporosis

P. Miller, 2003, Southern medical journal.

Greater Risk, Greater Benefit—True or False?

P. Miller, 2003 .

Controversial Issues in Bone Densitometry

P. Miller, 2002 .

Management of erections during transurethral surgery using ethyl chloride spray.

P. Miller, E. J. Galizia, 1993, British journal of urology.

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE

N. Watts, R. Recker, P. Miller, 2005, Current medical research and opinion.

Bone mineral density in elite junior Olympic weightlifters.

W J Kraemer, W. Kraemer, A. Fry, 1993, Medicine and science in sports and exercise.

Change in Lumbar Spine BMD and Vertebral Fracture Risk Reduction in Teriparatide‐Treated Postmenopausal Women With Osteoporosis

P. Delmas, P. Miller, J. Krege, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.

T. Keaveny, D. Kopperdahl, M. Kleerekoper, 2014, The Journal of bone and joint surgery. American volume.

Underdiagnosis and Undertreatment of Osteoporosis: The Battle to Be Won.

P. Miller, 2016, The Journal of clinical endocrinology and metabolism.

Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions.

N. Watts, W. Leslie, P. Miller, 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

P. Miller, M. McClung, G. Hattersley, 2018, Calcified Tissue International.

DXA-generated Z-scores and T-scores may differ substantially and significantly in young adults.

P. Miller, J. Carey, A. Licata, 2007, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Hypotensive sequelae of diazoxide and hydralazine therapy.

R. Anderson, W. Henrich, P. Miller, 1977, JAMA.

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate

C. Cooper, J. Reginster, D. Felsenberg, 2006, Osteoporosis International.

Cooled thermotherapy for the treatment of benign prostatic hyperplasia: durability of results obtained with the Targis System.

P. Miller, K. Parsons, C. Kastner, 2003, Urology.

Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions.

Anne-Marie Schott, Didier Hans, D. Bauer, 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

A novel transurethral microwave thermal ablation system to treat benign prostatic hyperplasia: results of a prospective multicenter clinical trial.

P. Miller, K. Parsons, E W Ramsey, 1997, The Journal of urology.

Preferential heating using transurethral thermoablation (T3) improves clinical results

Ernest W. Ramsey, P. D. Miller, K. F. Parsons, 1997, Photonics West - Biomedical Optics.

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies*

P. Miller, S. T. Harris, W. A. Blumentals, 2008, Current medical research and opinion.

Further Nonvertebral Fracture Reduction Beyond 3 Years for up to 10 Years of Denosumab Treatment.

P. Miller, C. Roux, E. Lewiecki, 2019, The Journal of clinical endocrinology and metabolism.

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group

J. Bilezikian, P. Miller, P. Ebeling, 2019, Osteoporosis International.

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

O. Tørring, J. Reginster, C. O’Malley, 2015, Osteoporosis International.

Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis

N. Watts, P. Miller, Dima L. Diab, 2013 .

Efficacy and safety of a once‐yearly i.v. Infusion of zoledronic acid 5 mg versus a once‐weekly 70‐mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double‐blind, active‐controlled study

Jacques P. Brown, J. Adachi, E. Orwoll, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Safety of bisphosphonates in the treatment of osteoporosis.

R. Recker, P. Miller, E. Lewiecki, 2009, The American journal of medicine.

Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate.

P. Miller, J. Body, J. Krege, 2005, The Journal of rheumatology.

Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study

D. Gold, S. Silverman, P. Miller, 2005, Osteoporosis International.

The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements?

E. Siris, R. Lindsay, M. Kleerekoper, 1998, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

2008 Santa Fe Bone Symposium: update on osteoporosis.

R. Eastell, J. Bilezikian, P. Miller, 2009, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Fracture Healing in Two Adult Patients With Hypophosphatasia After Asfotase Alfa Therapy

Steven W. Ing, P. Miller, J. Payne, 2018, JBMR Plus.

Unrecognized and unappreciated secondary causes of osteoporosis.

P. Miller, 2012, Endocrinology and metabolism clinics of North America.

Increases in BMD Correlate With Improvements in Bone Microarchitecture With Teriparatide Treatment in Postmenopausal Women With Osteoporosis

R. Recker, P. Miller, I. Pávó, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?

P. Miller, R. Derman, 2010, Osteoporosis International.

Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry.

H K Genant, R R Recker, J Dequeker, 1996, Seminars in arthritis and rheumatism.

Bone mineral density--clinical use and application.

P. Miller, 2003, Endocrinology and metabolism clinics of North America.

Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study

T. Weiss, C. McHorney, E. Barrett-Connor, 2007, Osteoporosis International.

Prediction of Fracture Risk in Postmenopausal White Women With Peripheral Bone Densitometry: Evidence From the National Osteoporosis Risk Assessment

E. Barrett-Connor, E. Siris, Ya-ting Chen, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Balloon dilatation of the prostate--should it have a place in the urologist's armamentarium?

P. Miller, R. Kirby, J. Vale, 1993, Journal of the Royal Society of Medicine.

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.

S. Boonen, P. Delmas, N. Watts, 2008, The Journal of clinical endocrinology and metabolism.

Bone Density Testing: Science, the Media, and Patient Care

J. Bilezikian, P. Miller, E. Lewiecki, 2014, Current Osteoporosis Reports.

More bone density testing is needed, not less

J. Bilezikian, P. Miller, E. Lewiecki, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: Is treatment with bisphosphonates an option?

P. Miller, A. Modi, R. Lubwama, 2014, Osteoporosis International.

Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone Diseases.

N. Watts, J. Bilezikian, D. Krakow, 2019, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Dual-energy X-ray absorptiometry diagnostic discordance between Z-scores and T-scores in young adults.

P. Miller, J. Carey, A. Licata, 2009, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women

P. Miller, M. Anger, B. Neal, 1991, Osteoporosis International.

Pitfalls in bone mineral density measurements

P. Miller, 2004, Current osteoporosis reports.

Bone mass measurements.

P. Miller, 2003, Clinics in geriatric medicine.

Use and Misuse of Peripheral Bone Densitometry

P. Miller, 2002 .

Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001.

N. Watts, L. Lenchik, P. Miller, 2002, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Diagnosis and Management of Osteoporosis: Guidelines for the Utilization of Bone Densitometry

H. Genant, P. Miller, R. Pacifici, 1997, Calcified Tissue International.

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the national osteoporosis risk assessment

Paul D. Miller, E. Barrett-Connor, E. Siris, 2002 .

Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis

E. McCloskey, B. Mitlak, J. Bilezikian, 2020, Current medical research and opinion.

Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study

B. Mitlak, A. Schwartz, D. Hans, 2020, JBMR plus.

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women

P. Miller, 2017, Annals of Internal Medicine.

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

R. Recker, C. Benhamou, P. Miller, 2011, Osteoporosis International.

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend

B. Mitlak, P. Miller, L. Fitzpatrick, 2019, Bone reports.

95 – The Clinical Application of Gender-Based Databases for the Diagnosis of Osteoporosis and Fracture Risk Prediction

P. Miller, 2004 .

Effects of furosemide and acetylcholine in norepinephrine-induced acute renal failure.

R. Schrier, P. Miller, A. Torrenté, 1978, The American journal of physiology.

The Osteoporosis Primer: Bone mineral density measurements

P. Miller, C. Zapalowski, 2000 .

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data

C. Cooper, J. Reginster, S. Silverman, 2009, Osteoporosis International.

Weekly Oral Alendronic Acid in Male Osteoporosis

T. Schnitzer, E. Orwoll, P. Miller, 2004, Clinical drug investigation.

Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.

P. Miller, C. Mautalen, Francisco Ramirez, 2011, Bone.

Four-year Results of a Phase 2 Study of the Cathepsin K Inhibitor Odanacatib in Postmenopausal Women with Low Bone Mineral Density: Effects on Bone Mineral Density and Bone Turnover Markers

I. Reid, J. Eisman, P. Miller, 2011 .

Controversies in Bone Mineral Density Diagnostic Classifications

P. Miller, 2000, Calcified Tissue International.

Use of lowest single lumbar spine vertebra bone mineral density T-score and other T-score approaches for diagnosing osteoporosis and relationships with vertebral fracture status.

P. Miller, N. Binkley, K. Krohn, 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Uses and misuses of quantitative ultrasonography in managing osteoporosis.

P. Miller, E. Lewiecki, B. Richmond, 2006, Cleveland Clinic journal of medicine.

Hypocalciuric effect of lithium in man.

S. Dubovsky, R. Schrier, P. Miller, 1977, Advances in experimental medicine and biology.

History of etidronate.

W. Mysiw, H. Genant, N. Watts, 2020, Bone.

Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis

E. Glass, R. Lindsay, P. Miller, 2009, Osteoporosis International.

Erratum: Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long‐term continuation on bone turnover and fracture risk—A perspective

S. Boonen, I. Reid, P. Sambrook, 2012 .

Erratum: Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long‐term continuation on bone turnover and fracture risk—A perspective

S. Boonen, I. Reid, P. Sambrook, 2012 .

Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA)

T. Weiss, C. McHorney, E. Barrett-Connor, 2009, Osteoporosis International.

Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study

R. Rizzoli, I. Reid, C. Benhamou, 2016, Osteoporosis International.

Presidential Message: Journal of Clinical Densitometry

P. Miller, 1998 .

The use of risedronate in Paget's disease.

P. Miller, 1999, Bone.

Distinction between the common symptoms of the phosphate-depletion syndrome and glucocorticoid-induced disease.

P. Miller, C. Solomons, M. Goodman, 1978, The American journal of medicine.

The effect of potassium loading on sodium excretion and plasma renin activity in Addisonian man.

P. Miller, E. Cohen, C. Waterhouse, 1975, The Journal of clinical investigation.

Eosinophilic prostatitis and prostatic specific antigen.

T. Christmas, P. Miller, R. Kirby, 1992, British journal of urology.

The rationale for intermittent administration of PTH in the management of mineral and bone disorder of chronic kidney disease

P. Miller, M. Pazianas, 2023, Journal of nephrology.

rti , . : ll ' Secondary and Tertiary Hyperparathyroidism

S. Jamal, P. Miller, 2017 .

Cyclical etidronate treatment of postmenopausal osteoporosis: 4 year experience

H. Genant, N. Watts, P. Miller, 1992 .

Osteoporosis: A Guide for Clinicians

P. Miller, P. Camacho, 2007 .

Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.

N. Watts, E. Orwoll, P. Miller, 2000, American family physician.

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

D. Kiel, S. Silverman, H. Genant, 2000, The American journal of medicine.

OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome

R. Kumar, J. S. San Martin, P. Miller, 2019, Journal of the Endocrine Society.

Higher urine desmosine levels are associated with mortality in patients with acute lung injury.

Arthur S Slutsky, W. Sibbald, T. Clemmer, 2006, American journal of physiology. Lung cellular and molecular physiology.

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis

N. Watts, P. Miller, G. Hattersley, 2019, Osteoporosis International.

Standard Techniques of Bone Mass Measurement in Adults

N. Watts, P. Miller, E. Lewiecki, 2018, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.

Unrecognized and unappreciated secondary causes of osteoporosis.

P. Miller, 2012, Endocrinology and metabolism clinics of North America (Print).

Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.

Jacques P. Brown, R. Recker, R. Lindsay, 2016, The Journal of clinical endocrinology and metabolism.

The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function

S. Cummings, S. Jamal, C. Stehman-Breen, 2010 .

The treatment of osteoporosis. Antiresorptive therapy.

P. Miller, 2000, Clinics in laboratory medicine.

Osteoporosis update from the 2010 santa fe bone symposium.

R. Marcus, N. Watts, S. Khosla, 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Clinical Management of Vertebral Compression Fractures.

P. Miller, 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women

P. Miller, G. Constantine, R. Kagan, 2016, Menopause.

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

J. S. San Martin, P. Miller, L. Grazette, 2011, The Journal of clinical endocrinology and metabolism.

Position Development Conference

N. Watts, L. Lenchik, P. Miller, 2003, Southern medical journal.

COMMENTARY Bone Densitometry: The Best Way to Detect Osteoporosis and to Monitor Therapy

J. Bilezikian, P. Miller, C. M. Kulak, 2009 .

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016.

N. Watts, M. Kleerekoper, Rachel Pessah-Pollack, 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Reply to Letter to the Editor: Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease

P. Miller, Zhi-hong Yu, 2023, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease

I. Reid, J. Adachi, P. Miller, 2022, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases

N. Watts, J. Bilezikian, P. Miller, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

P. Miller, M. McClung, G. Hattersley, 2017, Calcified Tissue International.

Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.

S. Cummings, N. Pannacciulli, P. Miller, 2016, The Journal of clinical endocrinology and metabolism.

Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report.

S. Jamal, P. Miller, D. Goltzman, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Diagnosis and treatment of osteoporosis in chronic renal disease.

P. Miller, 2009, Seminars in nephrology.

Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBDs): What the Endocrinologist Needs to Know.

N. Watts, P. Miller, F. Zangeneh, 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.